Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine Development

A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines

(2011) Oliver Koeberling et al.   Clinical and Vaccine Immunology

Measurement of Functional Anti-Meningococcal Serogroup A Activity Using Strain 3125 as the Target Strain for Serum Bactericidal Assay

(2011) Jan T. Poolman et al.   Clinical and Vaccine Immunology

Meningococcal Group W-135 and Y Capsular Polysaccharides Paradoxically Enhance Activation of the Alternative Pathway of Complement

(2011) Sanjay Ram et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination

(2011) P. T. Beernink et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys

(2011) Oliver Koeberling et al.   VACCINE

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

(2011) David M. Vu et al.   VACCINE

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression

(2011) P.B. Keiser et al.   VACCINE

Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement

(2010) C Alexandre et al.   ACTA PAEDIATRICA

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial

(2010) K. P. Perrett et al.   CLINICAL INFECTIOUS DISEASES

The epidemiology of meningococcal disease and the impact of vaccines

(2010) Ameneh Khatami et al.   Expert Review of Vaccines

Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies

(2010) Kate L. Seib et al.   INFECTION AND IMMUNITY

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

(2010) Wendell D. Zollinger et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa

(2010) Kedibone M. Mothibeli et al.   VACCINE

Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete

(2010) William P. Hanage et al.   Epidemics

The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

(2010) Lisa A. Lewis et al.   PLoS Pathogens

Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity

(2009) J. S. Plested et al.   Clinical and Vaccine Immunology

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

The modular architecture of meningococcal factor H-binding protein

(2009) P. T. Beernink et al.   MICROBIOLOGY-SGM

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution

(2009) F. Marc LaForce et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2

(2008) O. Koeberling et al.   Clinical and Vaccine Immunology

Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia

(2008) D. Chiavolini et al.   Clinical and Vaccine Immunology

Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines

(2008) P. T. Beernink et al.   INFECTION AND IMMUNITY

Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein

(2008) P. T. Beernink et al.   INFECTION AND IMMUNITY

Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

(2008) D. M. Granoff et al.   INFECTION AND IMMUNITY

B:2a:P1.5 Meningococcal Strains Likely Arisen from Capsular Switching Event Still Spreading in Spain

(2008) J. Castilla et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Bactericidal Antibody Responses Elicited by a Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Factor H–Binding Protein and Genetically Attenuated Endotoxin

(2008) Oliver Koeberling et al.   JOURNAL OF INFECTIOUS DISEASES

Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine Antigen

(2008) Jo Anne Welsch et al.   JOURNAL OF INFECTIOUS DISEASES

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

(2008) Che-Hung Lee et al.   VACCINE